Journal articles: 'Groupes discontinus'

1

Saloff-Coste, L. "Opérateurs pseudo-différentiels sur certains groupes totalement discontinus." Studia Mathematica 83, no. 3 (1986): 205–28. http://dx.doi.org/10.4064/sm-83-3-205-228.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

TERADA, Toshiaki. "Fonctions hypergéométriques $F_{1}$ et fonctions automorphes II. Groupes discontinus arithmétiquement définis." Journal of the Mathematical Society of Japan 37, no. 2 (April 1985): 173–85. http://dx.doi.org/10.2969/jmsj/03720173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Baklouti, Ali, Souhail Bejar, and Khaireddine Dhahri. "Deforming discontinuous groups for Heisenberg motion groups." International Journal of Mathematics 30, no. 09 (August 2019): 1950045. http://dx.doi.org/10.1142/s0129167x19500459.

Full text

Abstract:

We study in this paper the local rigidity proprieties of deformation parameters of the natural action of a discontinuous group [Formula: see text] acting on a homogeneous space [Formula: see text], where [Formula: see text] stands for a closed subgroup of the Heisenberg motion group [Formula: see text]. That is, the parameter space admits a locally rigid (equivalently a strongly locally rigid) point if and only if [Formula: see text] is finite. Moreover, Calabi–Markus’s phenomenon and the question of existence of compact Clifford–Klein forms are also studied.

APA, Harvard, Vancouver, ISO, and other styles

4

Shalom, Avshalom, Doron Klein, Tal Friedman, and Melvyn Westreich. "Lack of Complications in Minor Skin Lesion Excisions in Patients Taking Aspirin or Warfarin Products." American Surgeon 74, no. 4 (April 2008): 354–57. http://dx.doi.org/10.1177/000313480807400417.

Full text

Abstract:

Many patients undergoing surgical procedures take medications that influence the coagulation system. It is common practice to discontinue the use of aspirin and warfarin products 7 to 10 days before any major surgical procedure. However, there is some controversy as to whether these medications should be discontinued for minor dermatological procedures. Our aim was to study the incidence of complications in patients receiving aspirin or warfarin and undergoing minor dermatological procedures. Two thousand three hundred twenty-six patients, operated on by a single surgeon, were studied for complications. Warfarin was used by 28 patients, 228 took aspirin, and the remainder took neither. There was no difference in the complication rate among the three groups as long as the surgeon diligently obtained hemostasis. It appears that patients taking aspirin or warfarin do not need to discontinue these medications before minor dermatological procedures.

APA, Harvard, Vancouver, ISO, and other styles

5

Deo, Satya, and K. Varadarajan. "Discrete Groups and Discontinuous Actions." Rocky Mountain Journal of Mathematics 27, no. 2 (June 1997): 559–83. http://dx.doi.org/10.1216/rmjm/1181071925.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lim, Wendy, Myra Wang, Karen Woods, Mark Crowther, and James Douketis. "The Management of Anticoagulated Patients Requiring Dental Extraction: A Cross-Sectional Survey of Oral Surgeons and Hematologists." Blood 108, no. 11 (November 16, 2006): 629. http://dx.doi.org/10.1182/blood.v108.11.629.629.

Full text

Abstract:

Abstract Background: Studies in the dental literature and guidelines from the American Dental Association (ADA) and American College of Chest Physicians (ACCP) suggest that oral anticoagulants do not need to be discontinued prior to dental extraction. Despite this, anticoagulants are routinely discontinued due to perceived risks in bleeding. This practice may place patients at avoidable risk of thromboembolic complications. Objectives: To compare how oral surgeons and hematologists manage patients receiving long-term vitamin K antagonists (warfarin) who also require dental extraction. Design: Cross-sectional survey. Methods: Pre-tested surveys were mailed to 168 oral and maxillofacial surgeons and 123 hematologists/thromboembolism specialists licensed to practice in Ontario, Canada. The survey consisted of 3 parts: an assessment of bleeding and thrombotic risk factors that influence practioners’ decision to discontinue anticoagulants, individual scenarios assessing practice patterns, and clinical scenarios with varying risks of bleeding and thrombosis. For the clinical scenarios, respondents were asked to rate their risk perception on a 10-point scale, and the means and standard deviations of the responses between oral surgeons and hematologists were compared using unpaired t-tests, SPSS Version 12.0. Results: A total of 291 surveys were mailed with a response rate of 47% (136 surveys). 82 (60%) of the respondents were oral surgeons (75% community-based, 25% academic) and 54 (40%) were hematologists (28% community-based, 72% academic). Warfarin is routinely discontinued at least 50% of the time by 37% of dental surgeons, compared to 71% of hematologists; 29% of hematologists reported always discontinuing warfarin. The 3 main factors that influence oral surgeons’ and hematologists’ decision to discontinue warfarin are complicated procedures, multiple extractions and patients with a prior history of bleeding; 20% of hematologists discontinue anticoagulants because of specific referral to manage anticoagulants around the time of extraction. The maximum international normalized ratio (INR) that hematologists consider acceptable for extraction is 2.0, with no hematologists recommending extraction above this level; 86% of oral surgeons would proceed with extraction with an INR up to 3.0. In the individual scenarios, oral surgeons are more likely to continue warfarin and use local measures (sutures, gelfoam) to control bleeding. Hematologists are more likely to discontinue warfarin, use bridging anticoagulant therapy and recommend antifibrinolytic agents. In the clinical scenarios assessing thrombotic risk, oral surgeons are more likely to perceive that the risk of thrombosis is higher than hematologists (p < 0.01). In contrast, in the clinical scenarios assessing bleeding risk, the risk of bleeding was rated to be similar by both groups. Conclusions: Despite ADA and ACCP recommendations to continue anticoagulant therapy in most patients undergoing dental procedures, over 70% of hematologists, and 37% of dental surgeons in our survey frequently discontinue anticoagulants. Although the cited reasons for discontinuation are similar between the 2 groups, the frequency of discontinuation is significantly lower in oral surgeons and may be related to the perception that thromboembolic risks are high compared to hematologists’ risk assessments.

APA, Harvard, Vancouver, ISO, and other styles

7

Tur, Carmen, Mar Tintoré, Angela Vidal-Jordana, Joaquín Castilló, Ingrid Galán, Jordi Río, Georgina Arrambide, et al. "Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision." Multiple Sclerosis Journal 18, no. 8 (March 1, 2012): 1193–96. http://dx.doi.org/10.1177/1352458512439238.

Full text

Abstract:

Multifocal progressive leukoencephalopathy (PML) is associated with JC virus (JCV) seropositivity, past immunosuppression, and natalizumab treatment for two years or more. The aim of our study was to investigate the rate of treatment discontinuation after stratifying for the three risk factors in a group of 104 natalizumab-treated patients with relapsing–remitting multiple sclerosis. We investigated JCV serological status in our population. We then divided patients into groups according to their PML risk. Treatment indication was reassessed. Of the patients, 64 (61.5%) were JCV seropositive. Amongst seropositive patients on natalizumab for 2 years or more, 10 had received immunosuppression (group A), and 38 had not (group B). After an informed and shared decision-making process, 6/10 (60%) from group A compared with 9/38 (23.7%) from group B discontinued treatment ( p=0.027). In groups A and B, discontinuation also depended upon doctors’ views ( p=0.019, group A; p=0.010, group B) and clinical outcomes ( p=0.021, group A). No-one from low–intermediate risk groups discontinued. The decision to discontinue natalizumab treatment is complex, even when clear PML risk rates are described. Clinical outcomes and doctors’ idiosyncrasies play a crucial part in patients’ final choice.

APA, Harvard, Vancouver, ISO, and other styles

8

Baklouti, Ali, and Souhail Bejar. "Variants of stability of discontinuous groups for Euclidean motion groups." International Journal of Mathematics 28, no. 06 (May 7, 2017): 1750046. http://dx.doi.org/10.1142/s0129167x1750046x.

Full text

Abstract:

Let [Formula: see text] be a Lie group, [Formula: see text] a closed subgroup of [Formula: see text] and [Formula: see text] a discontinuous group for the homogeneous space [Formula: see text]. Given a deformation parameter [Formula: see text], the deformed subgroup [Formula: see text] may fail to act properly discontinuously on [Formula: see text]. To understand this phenomenon in the case when [Formula: see text] stands for an Euclidean motion group [Formula: see text], we compare the notion of stability for discontinuous groups (cf. [T. Kobayashi and S. Nasrin, Deformation of properly discontinuous action of [Formula: see text] on [Formula: see text], Int. J. Math. 17 (2006) 1175–1193]) with its variants. We prove that the defined stability variants hold when [Formula: see text] turns out to be a crystallographic subgroup of [Formula: see text].

APA, Harvard, Vancouver, ISO, and other styles

9

Khlif, Fatma. "Stability of discontinuous groups for reduced threadlike Lie groups." International Journal of Mathematics 26, no. 08 (July 2015): 1550057. http://dx.doi.org/10.1142/s0129167x15500573.

Full text

Abstract:

Let G be a reduced threadlike Lie group, H an arbitrary closed connected subgroup of G and Γ ⊂ G an abelian discontinuous subgroup for G/H. We study in this work some topological properties of the parameter space [Formula: see text] and the deformation space [Formula: see text], namely the stability and the rigidity. Instead of treating stability, we consider a weaker form by using an explicit covering of Hom (Γ, G) which we call layering and we show that the local rigidity holds if and only if Γ is finite.

APA, Harvard, Vancouver, ISO, and other styles

10

Weidmann, Richard. "The rank of planar discontinuous groups." Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg 72, no. 1 (December 2002): 1–8. http://dx.doi.org/10.1007/bf02941660.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Vithanaarachchi, Nishanthi, Thimuthu Medagama, and Lakshika Nawarathna. "Assessment of contributing factors for discontinuation of orthodontic treatment." APOS Trends in Orthodontics 10 (June 30, 2020): 105–10. http://dx.doi.org/10.25259/apos_143_2019.

Full text

Abstract:

Objectives: The aims of this study were to assess the prevalence and associated contributory factors for discontinuation of orthodontic treatment. Materials and Methods: A hospital-based retrospective study was conducted with the treatment records, whose orthodontic treatment was commenced in the year 2015 at the Division of Orthodontics, University Dental Hospital, Peradeniya. Information regarding age, gender, type of malocclusion, Index of Orthodontic Treatment Need, appliance type, duration of treatment, extraction versus non-extraction, stage of treatment, and the cost of treatment was obtained from the patient’s records. Statistical analysis was performed using the statistical software R 3.5.0. Results: The sample consisted of 310 treatment cases, of which 40 (12.9%) patients were discontinued. Among the discontinued patients, 50.6% were male and 49.3% were female. The discontinuation rate in the group of 12–17 years was higher than the other age groups, which was statistically significant (P = 0.005). Among the group of discontinued treatment, 49.3% were of Class II division 1 malocclusion and 37.1% and 37.4% of patients were in Grade 3 and 4 of IOTN, respectively. About 37% of patients have been discontinued before completion of 1 year which was statistically significant (P = 0.0005). About 59.5% of non-extraction patients were in the treatment discontinuation group which was also statistically significant (P = 0.023). About 32.5% of the patients who discontinued have obtained the treatment with the lowest cost with statistical significance (P = 0.026). Conclusion: Children with borderline and moderate occlusal irregularities treated with simple removable appliances which are affordable with low cost were more prone to discontinue in the early phase of active treatment.

APA, Harvard, Vancouver, ISO, and other styles

12

Brennan, M. T., M. A. Valerin, J. L. Noll, J. J. Napeñas, M. L. Kent, P. C. Fox, H. C. Sasser, and P. B. Lockhart. "Aspirin Use and Post-operative Bleeding from Dental Extractions." Journal of Dental Research 87, no. 8 (August 2008): 740–44. http://dx.doi.org/10.1177/154405910808700814.

Full text

Abstract:

Aspirin is a common, chronically administered preventive treatment for cardiovascular disease, but is often discontinued prior to invasive dental procedures because of concern for bleeding complications. We hypothesized that aspirin does not cause increased bleeding following a single tooth extraction. Thirty-six healthy persons requiring a tooth extraction were randomized to receive 325 mg/day aspirin or placebo for 4 days. Cutaneous bleeding time (BT) and platelet aggregation tests were obtained prior to extraction. The primary outcome measure, oral BT, and secondary bleeding outcomes were evaluated during and following extraction. No significant baseline differences, except for diastolic blood pressure, were found between groups. There were no differences in oral BT, cutaneous BT, secondary outcome measures, or compliance. Whole-blood aggregation results were significantly different between the aspirin and placebo groups. These findings suggest that there is no indication to discontinue aspirin for persons requiring single-tooth extraction.

APA, Harvard, Vancouver, ISO, and other styles

13

Baklouti, Ali, Sonia Ghaouar, and Fatma Khlif. "Deforming discontinuous subgroups of reduced Heisenberg groups." Kyoto Journal of Mathematics 55, no. 1 (April 2015): 219–42. http://dx.doi.org/10.1215/21562261-2848169.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Smilga, Ilia. "Fundamental domains for properly discontinuous affine groups." Geometriae Dedicata 171, no. 1 (July 24, 2013): 203–29. http://dx.doi.org/10.1007/s10711-013-9895-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Nitsch, Edgar. "Der Keuper in der Stratigraphischen Tabelle von Deutschland 2016: kontinuierliche oder lückenhafte Überlieferung?" Zeitschrift der Deutschen Gesellschaft für Geowissenschaften 169, no. 2 (July 26, 2018): 181–201. http://dx.doi.org/10.1127/zdgg/2017/0129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Baklouti, A., M. Boussoffara, and I. Kedim. "Stability of Discontinuous Groups Acting on Homogeneous Spaces." Mathematical Notes 103, no. 3-4 (March 2018): 513–26. http://dx.doi.org/10.1134/s0001434618030197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Abernethy, Amy Pickar, Jean Kutner, Patrick Jud Blatchford, Christine Ritchie, Diane Fairclough, Laura Hanson, and Janet Bull. "Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness." Journal of Clinical Oncology 32, no. 18_suppl (June 20, 2014): LBA9514. http://dx.doi.org/10.1200/jco.2014.32.18_suppl.lba9514.

Full text

Abstract:

LBA9514 Background: For patients with life-threatening illness such as advanced cancer, optimal management of longstanding medications prescribed for comorbid illness is uncertain. Risks may outweigh benefits; e.g., benefits from HMG Co-A reductase inhibitors (“statins”) may take years to accrue and may not be relevant for a person with limited prognosis. Is it safe to discontinue statins for the patient with less than a year to live? Methods: This was a multicenter, unblinded pragmatic trial. At enrollment, participants were randomized (1:1) to discontinue or continue their statin medication. Eligible patients were adults with advanced life-limiting illness on a statin for ≥3 months for primary or secondary prevention, a life expectancy of greater than one month, and evidence of recent deterioration in performance status. Outcomes measured at baseline and at least monthly included survival, cardiovascular-related events, quality of life (QOL), symptoms, and polypharmacy. Rate of death within 60 days of randomization was the primary outcome. Results: 381 patients were enrolled (189 discontinue statins; 192 continue statins). Mean age was 74 years (SD 12); 22% were cognitively impaired; 49% had cancer as the primary diagnosis; and, 69% had used statins for >5 years. Rate of death within 60 days was not statistically different between groups (discontinue vs. continue, 23.8% vs. 20.3%, 90% CI -3.5% to 10.5%, p=0.36). The group discontinuing statins had longer median time-to-death (229 days [90% CI 186–332] vs. 190 days [90% CI 170-257]; p=0.60). Total QOL was significantly better among the group discontinuing statins (McGill QOL: 7.11 vs. 6.85, p=0.037) and there were fewer symptoms in this group (Edmonton Symptom Assessment Scale: 25.2 vs. 27.4, p=0.128). People in the discontinue statins group took significantly fewer medications (10.1 vs. 10.8, p = 0.034). Few participants in either group experienced cardiovascular events (13 vs. 11). Conclusions: In the setting of life-limiting illness such as advanced cancer, it is unlikely that harm will accrue when statins being used for primary or secondary prevention are discontinued; these patients may even benefit. Clinical trial information: NCT01415934.

APA, Harvard, Vancouver, ISO, and other styles

18

Truta, Brindusa, Ira L. Leeds, Joseph K. Canner, Jonathan E. Efron, Sandy H. Fang, Azah Althumari, and Bashar Safar. "Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease." Inflammatory Bowel Diseases 26, no. 7 (October 31, 2019): 1110–17. http://dx.doi.org/10.1093/ibd/izz250.

Full text

Abstract:

Abstract Objectives Early discontinuation of infliximab (IFX) in pregnant women with inflammatory bowel disease (IBD) decreases the intrauterine fetal exposure to the drug but may increase the risk of disease flaring leading to poor pregnancy outcomes. In this study, we assessed the impact of early IFX discontinuation on mother’s disease activity and on their at-risk babies. Methods In a retrospective study of the Truven Health Analytics MarketScan database from 2011 to 2015, we compared IBD patients who discontinued IFX more than 90 days (“early IFX”) with those who discontinue IFX 90 days or less (“late IFX) before delivery. We evaluated the risk of flaring, defined by new steroid prescriptions, visits to emergency room and/or hospital admissions, the pregnancy outcomes, and the at-risk babies. Results After IFX discontinuation, the early IFX group (68 deliveries) required significantly more steroid prescriptions than the late IFX group (318 deliveries) to control disease activity (P < 001). There were more preterm babies in the early IFX group (P < 049), but no difference within the 2 groups was noticed in the rate of intrauterine growth retardation, small for gestation, and stillborn babies. Similarly, there was no increase in acute respiratory infections, development delays, and congenital malformations in babies of the mothers from the late IFX vs early IFX groups. Conclusions Steroid-free remission IBD mothers are at risk for disease flares and preterm babies when IFX is discontinued early in pregnancy. Continuation of IFX seems to be safe at least for the first year of life.

APA, Harvard, Vancouver, ISO, and other styles

19

Beppu, Takaaki, Yuichi Sato, Toshiaki Sasaki, Kazunori Terasaki, and Kuniaki Ogasawara. "NI-19 Use of 11C-methionine PET for decision of discontinuation of adjuvant chemotherapy with temozolomide." Neuro-Oncology Advances 2, Supplement_3 (November 1, 2020): ii14. http://dx.doi.org/10.1093/noajnl/vdaa143.062.

Full text

Abstract:

Abstract Background: The aim was to clarify whether positron emission tomography with 11C-methyl-L-methionine (met-PET) is useful to decide on discontinuation of TMZ-adjuvant therapy in patients with residual diffuse astrocytic tumor. Methods: Subjects were 44 patients with residual tumor comprising 17 with IDH1-mutant diffuse astrocytoma (DA), 13 with IDH1-mutant anaplastic astrocytoma (AA), and 14 with IDH1-wild glioblastoma (GB). All patients received TMZ-adjuvant chemotherapy (median, 12 courses), and whether to discontinue or continue TMZ-adjuvant chemotherapy was decided on the basis of the tumor-to-normal ratio in standardized uptake value from met-PET (T/N); patients with T/N < 1.6 immediately discontinued TMZ, and patients with T/N > 1.6 were either to continued or discontinued TMZ. Progression-free survival (PFS) was compared between patients with T/N > 1.6 and T/N < 1.6 in each tumor type. Median observation period was 434 days after met-PET scanning. Results: The number of patient who underwent recurrence was 10 in DA, 7 in AA, and 11 in GB. All patients showing T/N > 1.6 underwent tumor recurrence. PFS was significantly longer in patients with T/N < 1.6 than T/N > 1.6 in DA and AA (p < 0.01 in both types), but was no significant difference between 2 groups in GB (p = 0.06). Sixteen of 17 patients (94%) in DA and AA showed recurrence from residual tumor, whereas 4 of 11 patients (36%) in GB showed recurrent tumor at remote regions which were different from residual tumor. Conclusions: The present study suggested that met-PET is beneficial to decide to discontinue adjuvant chemotherapy with TMZ in patients with residual tumors of DA and AA, but not useful for patients with GB. Reasons for unsuccessful results in GB might have been small sample size, failure of establishing the cut off value in T/N, recurrences at remote regions where not be assessed by met-PET.

APA, Harvard, Vancouver, ISO, and other styles

20

MATSUMOTO, KEIJI, and MASAAKI YOSHIDA. "INVARIANTS FOR SOME REAL HYPERBOLIC GROUPS." International Journal of Mathematics 13, no. 04 (June 2002): 415–43. http://dx.doi.org/10.1142/s0129167x02001320.

Full text

Abstract:

For several discontinuous groups acting on the hyperbolic 3-space, which are commensurable with the group arising from the Whitebread link complement, we construct systems of invariant functions, in terms of theta functions, which give explicit projective embeddings of the quotient spaces.

APA, Harvard, Vancouver, ISO, and other styles

21

Friedland, Shmuel. "Properly discontinuous groups acting on certain matrix homogeneous spaces." Linear and Multilinear Algebra 43, no. 1-3 (January 1997): 151–67. http://dx.doi.org/10.1080/03081089708818522.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Lučić, Z., and E. Molnár. "Fundamental domains for planar discontinuous groups and uniform tilings." Geometriae Dedicata 40, no. 2 (November 1991): 125–43. http://dx.doi.org/10.1007/bf00145910.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Adeleke, S. A. "Discontinuous automorphisms of the proper Galilei and Euclidean groups." International Journal of Theoretical Physics 28, no. 4 (April 1989): 469–79. http://dx.doi.org/10.1007/bf00673297.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Peterfy, Charles, Joel Kremer, William Rigby, Nora Singer, Christine Birchwood, Darcy Gill, William Reiss, Jinglan Pei, and Margaret Michalska. "Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy." Journal of Rheumatology 47, no. 3 (June 1, 2019): 325–32. http://dx.doi.org/10.3899/jrheum.180953.

Full text

Abstract:

Objective.To assess differences in joint damage and inflammation using magnetic resonance imaging (MRI) between patients with rheumatoid arthritis (RA) who achieved low disease activity with tocilizumab (TCZ) + methotrexate (MTX) and subsequently continued or discontinued MTX.Methods.In the COMP-ACT trial, US patients with RA received subcutaneous TCZ 162 mg + MTX. Those who achieved 28-joint count Disease Activity Score calculated with erythrocyte sedimentation rate (DAS28-ESR) ≤ 3.2 at Week 24 were randomized 1:1 (double-blind) to discontinue MTX (TCZ monotherapy; mono) or continue TCZ + MTX until Week 52. In a subset of patients, 1.5-Tesla MRI was used to obtain images of bilateral hands and wrists at weeks 24 and 40. Outcomes included changes in MRI-assessed synovitis, osteitis, erosion, and cartilage loss from Week 24 to Week 40, and in the proportion of patients with progression of each score.Results.Of 296 patients who achieved DAS28-ESR ≤ 3.2 at Week 24, 79 were enrolled in the pilot MRI substudy and randomized to TCZ mono (n = 38) or TCZ + MTX (n = 41). Treatment with either TCZ mono or TCZ + MTX suppressed erosion progression, synovitis, osteitis, and cartilage loss. The proportion of patients with no progression in each outcome measure was similar between groups (range, TCZ mono: 84.8–97.0%; TCZ + MTX: 92.3–100%).Conclusion.In a subset of patients who achieved low disease activity with TCZ + MTX, MRI changes were minimal in intraarticular inflammation and damage measures in patients who discontinued MTX versus those who continued TCZ + MTX.

APA, Harvard, Vancouver, ISO, and other styles

25

Edwards, Kathryn C., Eva Sharma, Michael J. Halenar, Kristie A. Taylor, Karin A. Kasza, Hannah Day, Hoda T. Hammad, et al. "Longitudinal pathways of exclusive and polytobacco cigar use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1–3 (2013–2016)." Tobacco Control 29, Suppl 3 (April 22, 2020): s163—s169. http://dx.doi.org/10.1136/tobaccocontrol-2020-055624.

Full text

Abstract:

ObjectiveThe goal of this study is to examine the cross-sectional prevalence of use and 3-year longitudinal pathways of cigar use in US youth (12-17 years), young adults (18-24 years), and adults 25+ (25 years or older).DesignData were drawn from the first three waves (2013–2016) of the Population Assessment of Tobacco and Health Study, a nationally representative, longitudinal cohort study of US youth and adults. Respondents with data at all three waves (youth, n=11 046; young adults, n=6478; adults 25+, n=17 188) were included in longitudinal analyses.ResultsWeighted cross-sectional prevalence of past 30-day (P30D) use was stable for adults 25+ (~6%), but decreased in youth (Wave 1 (W1) to Wave 3 (W3)=2.5% to 1.2%) and young adults (W1 to W3=15.7% to 14.0%). Among W1 P30D cigar users, over 50% discontinued cigar use (irrespective of other tobacco use) by Wave 2 (W2) or W3. Across age groups, over 70% of W1 P30D cigar users also indicated P30D use of another tobacco product, predominantly cigar polytobacco use with cigarettes. Discontinuing all tobacco use by W2 or W3 was greater in adult exclusive P30D cigar users compared with polytobacco cigar users.ConclusionsAlthough the majority of P30D cigar users discontinued use by W3, adult polytobacco users of cigars were less likely to discontinue all tobacco use than were exclusive cigar users. Tracking patterns of cigar use will allow further assessment of the population health impact of cigars.

APA, Harvard, Vancouver, ISO, and other styles

26

Anjum, Mehwish, Nilofar Mustafa, Qurratulain Mushtaq, Pakeza Aslam, Saima Qamar, and Riffat Sarwar. "COMPARISON OF FREQUENCY OF ABNORMAL FETAL HEART RATE IN CONTINUOUS VERSUS DISCONTINUOUS USE OF OXYTOCIN INFUSION FOR AUGMENTATION OF LABOUR." PAFMJ 71, no. 3 (June 29, 2021): 836–39. http://dx.doi.org/10.51253/pafmj.v71i3.3680.

Full text

Abstract:

Objective: To compare the frequency of abnormal fetal heart rate in continuous versus discontinuous use of oxytocin infusion for augmentation of labour. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Obstetrics and Gynaecology, Combined Military Hospital Lahore, from Feb to Aug 2018. Methodology: After fulfilling the inclusion criteria, 76 patients were equally divided in two groups A and B. In both groups, at 3 cm dilatation, intravenous infusion of 5 IU oxytocin in 500 cc normal saline was initiated at infusion rate 3.3mIU/minute Carditocography was initiated 10 minutes before infusion and then continued. An increment in infusion of 3.3mIU/minute was done every 20 minutes till 4 to 5 contractions in 10 minutes were achieved. After this, no more increment was done. The maximum rate was 30mIU/minute. Once cervix was 5 cm dilated, infusion was continued in group A and discontinued in group B for 2 hours. Fetal heart rate was noted on cardiotocography from 20 minutes before initiation of infusion till 2 hours after 5cm. Results: Age of the patients was 25.4 ± 3.5 years in group A and 26.1 ± 2.4 years in group B. Mean gestation age was 39.2 ± 1.1 weeks in group A and 38.6 ± 1.3 weeks in group B. Group A had significantly more abnormal fetal heart rate compared to group B (p=0.016). Conclusion: Discontinuous oxytocin infusion in labour showed significantly less abnormal fetal heart rate compared to continuous oxytocin infusion (p=0.016).

APA, Harvard, Vancouver, ISO, and other styles

27

Kobayashi, T., S. Motoya, S. Nakamura, T. Yamamoto, M. Nagahori, S. Tanaka, T. Hisamatsu, et al. "DOP39 The first prospective, multicentre, randomised controlled trial on discontinuation of infliximab in ulcerative colitis in remission; endoscopic normalisation does not guarantee successful withdrawal." Journal of Crohn's and Colitis 14, Supplement_1 (January 2020): S076—S077. http://dx.doi.org/10.1093/ecco-jcc/jjz203.078.

Full text

Abstract:

Abstract Background Anti-tumour necrosis factor (TNF)-α agents are the mainstay of the long-term treatments for refractory ulcerative colitis (UC). However, there is no prospective randomised controlled trial evaluating if anti-TNF-α agents can be discontinued in UC patients in remission. Methods Patients with UC maintained in clinical remission with infliximab (IFX) were prospectively enrolled from 23 specialist centres. Patients confirmed to be in (1) clinical remission for > 6 months, (2) steroid-free and (3) Mayo endoscopic subscore (MES) of 0 or 1 were randomised with stratified factors (MES and use of immunomodulators) into two groups (continue or discontinue IFX) in 1:1. The biopsy was taken from the rectum and Nancy histological Index (NI) was centrally scored at randomisation. The primary endpoint was remission rate at week 48 in full analysis set (FAS). Factors associated with remission at Week 48 were evaluated by logistic regression adjusted for the treatment group. Efficacy and safety of retreatment with IFX after relapse were also evaluated. Results A total of 92 patients were included in the FAS and the remission rates at week 48 were 80.4% (95% CI: 66.1–90.6) and 54.3% (95% CI: 39.0–69.1) in IFX-continued and IFX-discontinued groups, respectively (p = 0.008). Although the duration of IFX, use of concomitant immunomodulators, IFX concentration, and MES of 0 at randomisation were not predictive, C-reactive protein and NI were associated with remission at week 48 in FAS (p = 0.039 and 0.019, respectively). Retreatment with IFX lead to remission in 8 out of 12 patients (66.7%) in 8 weeks and was well-tolerated. Conclusion This first prospective multicentre randomised controlled trial confirmed that discontinuation of maintenance IFX resulted in the increased risk of relapse but retreatment was effective in UC. Endoscopic normalisation was not sufficient for the successful discontinuation of IFX.

APA, Harvard, Vancouver, ISO, and other styles

28

Kreutzman, Anna, Peter Rohon, Edgar Faber, Karel Indrak, Vesa Juvonen, Veli Kairisto, Jaroslava Voglova, et al. "Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile." Blood 116, no. 21 (November 19, 2010): 1201. http://dx.doi.org/10.1182/blood.v116.21.1201.1201.

Full text

Abstract:

Abstract Abstract 1201 Background. Before the era of tyrosine kinase inhibitors (TKIs), interferon alpha (IFN-α) was the treatment of choice in CML and prolonged survival of responding patients. Recent studies suggest that combination of IFN-α with TKI improves therapy outcome. Significantly, a proportion of IFN-α treated patients in prolonged complete cytogenetic remission (CCyR) have been able to discontinue treatment without disease relapse (Mahon et al. JCO 2002). The mechanism of action of IFN-α therapy is incompletely understood; the drug exerts both direct cytotoxic and immunomodulatory effects on leukemic cells. The aim of this project was to study the immunomodulatory effects of IFN-α in CML patients in prolonged remission and isolate biological markers predicting response. Patients and methods. The study population consisted of CML patients treated with IFN-α monotherapy (n = 10, median therapy time 146 months, range 63–231 months) and CML patients who had discontinued IFN-α therapy but remained in remission for >2 years (n = 9, median therapy time 120 months, range 80–184; median time without therapy 53 months, range 24–96). None of the patients were previously treated with TKI therapy. In addition, non-CML patients (3 patients with essential trombocythemia and one patient with polycythemia vera) treated with IFN-α and healthy volunteers (n = 43) were included as controls. Lymphocyte populations in all four groups were characterized with comprehensive immunophenotyping panels. The clonality of T-cells was analyzed by a TCR γ/δ rearrangement assay by PCR. Lymphocytes were further sorted into CD3+ TCR αβ+ and CD3+ TCR γδ+ populations (n = 8). Additionally, plasma levels of 25 cytokines were measured with a multiplex bead-based cytokine assay (Luminex®). Results. The proportion of NK-cells from lymphocytes was significantly increased in IFN-α discontinued patients (median 26%, range 18–51%) compared to healthy volunteers (11%, 5–21%) or patients on IFN-α therapy (12%, 6–31%)(P=0.0005). Similarly the proportion of CD8+ cells from T-cells was significantly increased in both CML IFN-α groups (55% in IFN-α discontinued patients, 44% in IFN-α treated patients vs. 31% in healthy volunteers; P<0.05 for both groups). Also a larger proportion of T-cells expressed the long-term memory antigen CD45RO in IFN-α patients (74%, 58% vs. 44% in healthy controls, P<0.01). The proportion of regulatory T-cells (CD4+CD25+FoxP3+) was increased in IFN-α groups (6.1%, 5.2% vs. 3.8% in healthy volunteers, P=0.01). Similar changes in immunoprofile were not observed in IFN-treated non-CML patients. Clonal TCR γ/δ rearrangements were observed in 18 of 19 (95%) IFN-treated CML patients as compared to 3 of 22 (14%) in healthy volunteers (P<0.01). In both IFN-α CML patient groups a unique rearrangement pattern was observed: 14/19 (79%) of patients had the Vγ9 gene clonally rearranged. This clonal rearrangement resided in CD3+ γδ+ T-cell population, as assessed by cell sorting. Two of four non-CML patients treated with IFN-α had the same clonal rearrangement, as well as one healthy control (1/22; 5%). Similar clonality patterns have not been observed in dasatinib or imatinib treated CML patients (Kreutzman et al. Blood 2010). IFN-α treatment was associated with a distinct plasma cytokine profile in CML patients. IP-10, IL-6, IL-12, eotaxin, MCP-1, and IFN-γ levels were significantly increased in IFN-α treated CML patients. In particular, eotaxin and MCP-1 levels differed significantly between healthy controls and IFN-α patients who had successfully discontinued IFN-α therapy (428 vs. 1173 pg/ml, P<0.0001 and 107 vs. 459 pg/ml, P=0.0003, respectively). In IFN-α treated non-CML patients, eotaxin or MCP-1 levels were not increased. Conclusions. Our results show that IFN-α treatment induces distinct changes in the immunoprofile of CML patients. Patients who had successfully discontinued IFN-α therapy differed markedly from healthy controls. IFN-α therapy was associated with increased numbers of NK-cells and clonal γδ+ T-cells. These cells possess potent anti-leukemic activity and may contribute to the prolonged therapy responses in this group of patients. Furthermore, plasma cytokine profile could be a helpful biomarker when considering which patients can discontinue the IFN-α treatment without imminent disease relapse. Disclosures: Faber: BMS, Novartis: Consultancy, Honoraria. Porkka:BMS, Novartis: Consultancy, Honoraria, Research Funding. Mustjoki:BMS, Novartis: Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

29

Abels, Herbert, Grigori A. Margulis, and Grigori A. Soifer. "Properly discontinuous groups of affine transformations with orthogonal linear part." Comptes Rendus de l'Académie des Sciences - Series I - Mathematics 324, no. 3 (February 1997): 253–58. http://dx.doi.org/10.1016/s0764-4442(99)80356-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

DRAGER, LANCE D., ROBERT L. FOOTE, and DOUGLAS MCMAHON. "Observing Ergodic Translations on Compact Abelian Groups with Discontinuous Functions." IMA Journal of Mathematical Control and Information 6, no. 4 (1989): 441–63. http://dx.doi.org/10.1093/imamci/6.4.441.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Ohtake, Hiromi. "On discontinuous subgroups with parabolic transformations of the Möbius groups." Journal of Mathematics of Kyoto University 25, no. 4 (1985): 807–16. http://dx.doi.org/10.1215/kjm/1250521026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Cornelissen, Gunther, Fumiharu Kato, and Aristides Kontogeorgis. "Discontinuous groups in positive characteristic and automorphisms of Mumford curves." Mathematische Annalen 320, no. 1 (May 2001): 55–85. http://dx.doi.org/10.1007/pl00004470.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Torikai, E., Y. Hirano, D. Suzuki, and Y. Kanayama. "FRI0137 Discontinuation of baricitinib after achieving low disease activity in patients with rheumatoid arthritis in clinical practice; a multicenter observational study." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 651.2–651. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1546.

Full text

Abstract:

Background:Baricitinib (bari) is an oral Janus kinase (JAK) 1/JAK2 selective inhibitor that has shown good efficacy in patients with RA and adequate response to conventional synthetic DMARDs in some clinical trials [1,2]. However, concerning the high cost and long-term safety related to the inhibition of particular molecules, we would like to discontinue bari after achieving long low disease activity (LDA).Objectives:To evaluate the clinical outcomes in patients with RA who discontinued bari after achieving LDA for 24 weeks in real-world multicenter clinical data.Methods:Japanese 67 patients with RA who show an inadequate response to csDMARDs or bDMARDs were scheduled to receive bari 4 or 2 mg/day once daily dose as a monotherapy or in combination with other csDMARDs. We included 51 patients who achieved and maintained LDA at least for 24 weeks after baricitinib therapy. They were allowed to decrease baricitinib after discontinuation of prednisolone. Bari was either discontinued or continued after study enrolment. The decision of discontinuation and continuation of baricitinib was determined based on patient-physician decision making with informed consent. We divided patients into two groups: a discontinuation group (D group; n = 23) and a continuation group (C group; n = 28). We evaluated the proportion of patients who remained LDA for 24 weeks in both groups. Clinical outcomes including Clinical Disease Activity Index (CDAI), and HAQ-DI were compared between both groups. The last observational carried forward method was used for patients who could not discontinue baricitinib due to flare before 24 weeks. In D group, patients were treated with re-initiation of bari or initiation of the other DMARDs in the event of flare. We investigated the serial changes of patients treated with re-initiation of bari in CDAI after flare.Results:The baseline characteristics of the patients are summarized in Table. The titer of RF was lower in D group than that in C group. There were no significant differences in any other items. Ten of 23 (43.4%) in D group remained bari-free without disease activity flare. Serial changes of CDAI were summarized in Figure. CDAI in D group significantly increased from 3.6 at baseline to 9.8 at last observation. LDA rates in C group were 92.9% at last observation. CDAI in C group did not change throughout the follow-up period. CDAI at last observation was higher in D group than that in C group. HAQ-DI in D group changed from 0.28 at baseline to 0.45 at last observation. There was no significant change in HAQ-DI between both groups (P = 0.28). In D group, rescue by re-administration of bari or other DMARDs induced improvement, reducing CDAI from 15.5 at disease flare to 6.8. Especially, all patients treated with re-initiation of bari resulted in re-introduction of LDA in this study.Table.Characteristics of patients at baricitinib initiationD group (n=23)C group (n=28)p-valueAge (years)66.9 (8.6)67.9 (12.7)0.31Gender, female, n (%)6 (73.9)24 (85.7)0.49Disease duration (years)7.6 (10.3)8.3 (9.9)0.37Prior use of biologics, n (0/1/2/≥3)(21/2/0/0)(17/6/4/1)------MTX (mg/w)5.5 (3.8)4.9 (4.3)0.62PSL (mg/d)1.4 (1.9)0.9 (0.9)0.51RF, U/ml99 (141)187 (214)0.04ACPA, U/ml135 (173)194 (214)0.11CDAI24.4 (9.2)22.5 (9.7)0.36HAQ-DI0.83 (0.49)0.83 (0.52)0.98Conclusion:It was possible to discontinue bari without flare in about 43% of patients with RA. Overall the patients treated with re-initiation of bari could result in re-introduction of LDA without deterioration of HAQ-DI.References:[1]Tanaka Y et al. Mod Rheumatol. 2018;28:583-91[2]Tanaka Y et al. Mod Rheumatol. 2018;28:20-9Disclosure of Interests:Eiji Torikai: None declared, Yuji Hirano Speakers bureau: Tanabe-Mitsubishi, Pfizer, Eisai, Abbie, Chugai, Bristol-Meyers, Jansen, Astellas, UCB, Eli-Lilly, Asahikasei, Daiichi-Sankyo, Amgen, Daisuke Suzuki: None declared, Yasuhide Kanayama: None declared

APA, Harvard, Vancouver, ISO, and other styles

34

Wyse, PhD, Jessica J., Benjamin J. Morasco, PhD, Steven K. Dobscha, MD, Michael I. Demidenko, BS, Thomas H. A. Meath, MPH, and Travis I. Lovejoy, PhD, MPH. "Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified." Journal of Opioid Management 14, no. 4 (July 1, 2018): 295–303. http://dx.doi.org/10.5055/jom.2018.0461.

Full text

Abstract:

Objective: Urine drug testing (UDT) is increasingly performed as a means of identifying aberrant behavior that may be grounds for discontinuation of long-term opioid therapy (LTOT). Little is known, however, about the ways in which positive UDT results may differentially inform decisions to discontinue LTOT based on the type of substance for which the UDT screened positive. The aim of this study was to examine the likelihood of clinician-initiated discontinuation of LTOT attributed to positive UDT results across three discrete categories of substances: (1) cannabis, (2) alcohol or illicit substances (excluding cannabis), and (3) controlled prescription medications that were not prescribed.Design: This retrospective study utilized the US Department of Veterans Affairs (VA) Health Care System. Corporate Data Warehouse to assemble a sample of 600 patients with substance use disorders and matched controls who were discontinued from LTOT in 2012. Comprehensive manual medical record review identified UDT results in the year prior to discontinuation and reason(s) for discontinuation.Patients, Participants: Patients with one or more UDTs positive for a single substance (N = 185) comprised the study sample.Main Outcome Measure(s): Likelihood of clinician-initiated discontinuation attributed to a positive UDT across the three categories. Results: Patients with one or more UDTs positive for cannabis were more likely to be discontinued from opioid therapy as a result of the positive UDT compared to those with one or more UDTs positive for nonprescribed prescription medication (adjusted odds ratio [OR] = 18.05, 95% CI = 7.29-44.66). Similarly, patients with UDTs positive for alcohol or illicit substances were more likely to be discontinued for the positive UDTs relative to patients who tested positive for nonprescribed prescription medications (adjusted OR = 13.10, 95% CI = 4.81-35.68). No difference in UDT-related discontinuation decisions was evident between patients with UDTs positive for alcohol/illicit substances versus cannabis (adjusted OR = 1.47, 95% CI = 0.57-3.77). Conclusions: High odds of UDT-related discontinuation were found in patients who tested positive for cannabis, alcohol, or illicit substances, relative to nonprescribed prescription medications.

APA, Harvard, Vancouver, ISO, and other styles

35

Mostow, G. D. "On discontinuous action of monodromy groups on the complex $n$-ball." Journal of the American Mathematical Society 1, no. 3 (September 1, 1988): 555. http://dx.doi.org/10.1090/s0894-0347-1988-0932662-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Golasiński, Marek, Daciberg Lima Gonçalves, and Rolando Jimenez. "Free and Properly Discontinuous Actions of Groups on Homotopy 2n-spheres." Proceedings of the Edinburgh Mathematical Society 61, no. 2 (February 8, 2018): 305–27. http://dx.doi.org/10.1017/s0013091517000207.

Full text

Abstract:

Let G be a group acting freely, properly discontinuously and cellularly on some finite dimensional CW-complex Σ(2n) which has the homotopy type of the 2n-sphere 𝕊2n. Then, that action induces a homomorphism G → Aut(H2n(Σ(2n))). We classify all pairs (G, φ), where G is a virtually cyclic group and φ: G → Aut(ℤ) is a homomorphism, which are realizable in the way above and the homotopy types of all possible orbit spaces as well. Next, we consider the family of all groups which have virtual cohomological dimension one and which act on some Σ(2n). Those groups consist of free groups and semi-direct products F ⋊ ℤ2 with F a free group. For a group G from the family above and a homomorphism φ: G → Aut(ℤ), we present an algebraic criterion equivalent to the realizability of the pair (G, φ). It turns out that any realizable pair can be realized on some Σ(2n) with dim Σ(2n) ≤ 2n + 1.

APA, Harvard, Vancouver, ISO, and other styles

37

Golasiński, M., D. L. Gonçalves, and R. Jimenez. "Free and properly discontinuous actions of discrete groups on homotopy circles." Russian Journal of Mathematical Physics 22, no. 3 (July 2015): 307–27. http://dx.doi.org/10.1134/s1061920815030036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Jespers, E., A. Kiefer, and Á. del Río. "Revisiting Poincaré’s Theorem on presentations of discontinuous groups via fundamental polyhedra." Expositiones Mathematicae 33, no. 4 (2015): 401–30. http://dx.doi.org/10.1016/j.exmath.2015.01.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Mostow, G. D. "On Discontinuous Action of Monodromy Groups on the Complex n-Ball." Journal of the American Mathematical Society 1, no. 3 (July 1988): 555. http://dx.doi.org/10.2307/1990949.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

BOWDITCH, B. H. "RELATIVELY HYPERBOLIC GROUPS." International Journal of Algebra and Computation 22, no. 03 (May 2012): 1250016. http://dx.doi.org/10.1142/s0218196712500166.

Full text

Abstract:

In this paper we develop some of the foundations of the theory of relatively hyperbolic groups as originally formulated by Gromov. We prove the equivalence of two definitions of this notion. One is essentially that of a group admitting a properly discontinuous geometrically finite action on a proper hyperbolic space, that is, such that every limit point is either a conical limit point or a bounded parabolic point. The other is that of a group which admits a cofinite action on a connected fine hyperbolic graph. We define a graph to be "fine" if there are only finitely many circuits a given length containing any given edge, and we develop some of the properties of this notion. We show how a relatively hyperbolic group can be assumed to act on a proper hyperbolic space of a particular geometric form. We define the boundary of a relatively hyperbolic group, and show that the limit set of any geometrically finite action of the group is equivariantly homeomorphic to this boundary. This generalizes a result of Tukia for geometrically finite kleinian groups. We also describe when the boundary is connected.

APA, Harvard, Vancouver, ISO, and other styles

41

Salma, N. "Proper Actions of Certain Nilpotent Affine Groups with Codimension One Orbits." Journal of Scientific Research 4, no. 2 (April 19, 2012): 315. http://dx.doi.org/10.3329/jsr.v4i2.7889.

Full text

Abstract:

Criterion for proper actions has been established for a homogeneous space of reductive type by Kobayashi (Math. Ann. 1989, 1996). On the other hand, an analogous criterion to Kobayashis equivalent conditions was proposed by Lipsman (1995) for a nilpotent Lie group . Lipsman's Conjecture: Let be a simply connected nilpotent Lie group. Then the following two conditions on connected subgroups and are equivalent: (i) the action of on is proper; (ii) is compact for any The condition (i) is important in the study of discontinuous groups for the homogeneous space , while the second condition (ii) can easily be checked. The implication (i) (ii) is obvious, and the opposite implication (ii) (i) was known only in some lower dimensional cases. In this paper we prove the equivalence (i) ? (ii) for certain affine nilpotent Lie groups . Keywords: Affine nilpotent groups; Homogeneous manifolds; Proper actions; Properly discontinuous actions; Simply connected nilpotent Lie groups; Compact isotropy property (CI); Eigenvalues. © 2012 JSR Publications. ISSN: 2070-0237 (Print); 2070-0245 (Online). All rights reserved. doi: http://dx.doi.org/10.3329/jsr.v4i2.7889 J. Sci. Res. 4 (2), 315-326 (2012)

APA, Harvard, Vancouver, ISO, and other styles

42

Okuda, Takayuki. "Homogeneous space with non-virtually abelian discontinuous groups but without any proper SL(2, ℝ)-action." International Journal of Mathematics 27, no. 03 (March 2016): 1650018. http://dx.doi.org/10.1142/s0129167x1650018x.

Full text

Abstract:

In the study of discontinuous groups for non-Riemannian homogeneous spaces, the idea of “continuous analogue” gives a powerful method (T. Kobayashi [Math. Ann. 1989]). For example, a semisimple symmetric space [Formula: see text] admits a discontinuous group which is not virtually abelian if and only if [Formula: see text] admits a proper [Formula: see text]-action (T. Okuda [J. Differ. Geom. 2013]). However, the action of discrete subgroups is not always approximated by that of connected groups. In this paper, we show that the theorem cannot be extended to general homogeneous spaces [Formula: see text] of reductive type. We give a counterexample in the case [Formula: see text].

APA, Harvard, Vancouver, ISO, and other styles

43

Rifkin, Robert M., Zoe Clancy, Ronda Copher, Kathleen M. Aguilar, Yiqiong Xie, Marley Boyd, and Chuck Wentworth. "A real-world comparative analysis of pomalidomide (POM) and other antimyeloma treatments following lenalidomide (LEN) discontinuation among patients with multiple myeloma." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e19337-e19337. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19337.

Full text

Abstract:

e19337 Background: In clinical trials, POM has demonstrated favorable clinical outcomes in patients with multiple myeloma (MM) who received prior LEN. Few studies, however, have examined POM treatment for MM in the community oncology setting. This retrospective cohort study compared treatment patterns and outcomes between patients who received a post-LEN treatment, either POM or another antimyeloma regimen. Methods: Adult patients with MM in the US Oncology Network (USON) who initiated a post-LEN treatment within 60 days of LEN discontinuation between Jan 1, 2016 and May 1, 2018, were not clinical trial participants, and had ≥ 2 subsequent clinic visits, were eligible. Data were sourced from USON’s iKnowMed electronic health records. Among patients observed to have discontinued treatment, time to treatment discontinuation (TTTD) was estimated from date of initiation of post-LEN treatment (index treatment) to date of discontinuation. Among patients who started a new treatment after the index treatment, time to next treatment (TTNT) was estimated from date of initiation of index treatment until date of initiation of the next treatment. TTTD and TTNT were analyzed using the Kaplan–Meier (KM) method across the whole study sample; patients who did not discontinue or start a next treatment were censored. Results: Of 547 eligible patients, 155 (28.3%) initiated POM and 392 (71.7%) initiated another antimyeloma regimen. Demographic characteristics were similar between the groups (for all patients, median age was 68 years, 54.5% patients were male and 71.7% were white). In total, 74.2% and 83.7% of patients discontinued the index treatment in the POM and other-treatment groups, respectively. Among the entire study population, KM estimates of median TTTD were 3.5 months (95% CI 2.8–4.6) and 1.9 months (95% CI 1.6–2.4) in the POM and other-treatment group, respectively (log-rank P < 0.001). In total, 65.2% and 71.2% of patients initiated subsequent treatment in the POM and other-treatment groups, respectively. KM estimates of median TTNT were 6.2 months (95% CI 4.5–7.8) and 4.5 months (95% CI 3.9–5.3) in the POM and other-treatment groups, respectively (log-rank P = 0.38). Conclusions: For patients with MM the use of POM following LEN treatment resulted in longer TTNT and TTTD compared with those who received other antimyeloma therapy. These findings support the use of POM treatment after LEN as an option for patients with relapsed/refractory MM.

APA, Harvard, Vancouver, ISO, and other styles

44

Rosenberg, Abby R., Courtney C. Junkins, Nicole Sherr, Samantha Scott, Victoria Klein, Krysta S. Barton, and Joyce P. Yi-Frazier. "Conducting Psychosocial Intervention Research among Adolescents and Young Adults with Cancer: Lessons from the PRISM Randomized Clinical Trial." Children 6, no. 11 (October 24, 2019): 117. http://dx.doi.org/10.3390/children6110117.

Full text

Abstract:

Background: Adolescents and young adults (AYAs) with cancer have poor psychosocial outcomes, in part because their limited participation in clinical trials precludes intervention-testing. We previously reported results of a successful randomized trial testing an AYA-targeted psychosocial intervention. Here, we aimed to describe strategies learned during the trial’s conduct. Methods: We summarized data from the medical record and staff field notes regarding reasons for participation/non-participation. We conducted two focus groups with study staff; directed content analyses identified strategies for success. Results: 92 AYAs enrolled (77% of approached; n = 50 Usual Care (control), n = 49 PRISM (intervention)). In eligible families who declined participation (n = 22 AYAs, n = 8 parents), the AYAs more commonly had advanced cancer (n = 11 (37%) declined vs. n = 25 (26%) enrolled). AYA reasons for non-enrollment were predominantly “not interested”; parents worried participation was “too burdensome.” Staff strategies for accrual included having significant time to introduce the study and underscoring a desire to learn from the patient. After enrollment, AYAs who discontinued participation were more commonly assigned to control (n = 5 (10%) control vs. n = 2 (4%) intervention). Only n = 1 AYA chose to discontinue participation after receiving the intervention. Conclusions: Efforts to engage AYAs prior to and during studies may help with accrual and retention.

APA, Harvard, Vancouver, ISO, and other styles

45

Weller, Belinda, Giancarlo Comi, Mark Freedman, Ludwig Kappos, Aaron Miller, Tomas Olsson, Jerry Wolinsky, Myriam Benamor, Philippe Truffinet, and Paul O'Connor. "EFFECT OF TERIFLUNOMIDE ON LYMPHOCYTE AND NEUTROPHIL COUNTS." Journal of Neurology, Neurosurgery & Psychiatry 86, no. 11 (October 14, 2015): e4.25-e4. http://dx.doi.org/10.1136/jnnp-2015-312379.120.

Full text

Abstract:

IntroductionTeriflunomide is an immunomodulator known to decrease the proliferation of stimulated lymphocytes via inhibition of dihydro-orotate dehydrogenase. Lymphocyte/neutrophil counts were assessed in pooled data from one phase 2 and three phase 3 (TEMSO, TOWER, and TOPIC) placebo-controlled studies.MethodsPatients were randomized to receive once-daily teriflunomide 14mg (n=1002), 7mg (n=1045), or placebo (n=997). Blood samples were collected throughout the studies.ResultsMean baseline lymphocyte and neutrophil counts were similar across groups. Small decreases in mean lymphocyte and neutrophil counts occurred within the first 12 weeks (lymphocytes) or 6 weeks (neutrophils) of treatment, and stabilized within the normal range for most patients thereafter. Patients with neutrophil counts <1×10^9^/L were to discontinue treatment; 11 (1.1%; 14 mg), 8 (0.8%; 7 mg), and 1 (0.1%; placebo) patients discontinued due to neutropenia or neutrophil count decrease as per protocol requirements. Neutropenia was reported as a serious adverse event (SAE) in 7 (0.7%; 14 mg), 2 (0.2%; 7 mg), and 3 (0.3%; placebo) patients; there were no lymphopenia SAEs. No link between neutrophil or lymphocyte count decreases and infection was observed.ConclusionsThese data demonstrate that teriflunomide has small, reversible effects on lymphocyte/neutrophil counts, with no increase in infection risk observed. (Study supported by Genzyme, a Sanofi company).

APA, Harvard, Vancouver, ISO, and other styles

46

Albert, Nikolai, Karl Ole Köhler-Forsberg, Carsten Hjorthøj, and Merete Nordentoft. "T214. ANTIPSYCHOTIC TREATMENT PATTERNS AND EFFECTS DURING THE EARLY YEARS AMONG 316 NEWLY DIAGNOSED PATIENTS WITH SCHIZOPHRENIA FROM THE OPUS TRIAL." Schizophrenia Bulletin 46, Supplement_1 (April 2020): S314. http://dx.doi.org/10.1093/schbul/sbaa029.774.

Full text

Abstract:

Abstract Background In studies investigating the relapse rate of psychotic symptoms in patients diagnosed with schizophrenia there is a discrepancy between discontinuation studies finding a relapse rate up to 90% after discontinuation of antipsychotic medication and long-term follow-up studies finding approx. 30% of patients living without antipsychotic medication and psychotic symptoms. Long-term follow-up studies often have multiple follow-up assessments, but little is known about the use of medication in the intervals between the follow-up points. While register studies can follow large cohorts of patients, they are unable to investigate psychopathology and level of functioning in patients who discontinue their medication. In this study we use data from a clinical cohort with information on participants symptoms and functioning and combine them with register data on the individual participants prescriptions and hospitalizations. Methods The present study represents a combination of a clinical study from early intervention settings and register-based information on antipsychotic drug use and hospital contacts. For the present study, patients were included 18 months into their 24 months early intervention treatment and followed up 3 ½ year later. At baseline and follow-up we performed clinical assessments with all patients and via the Danish National Hospital Register and the Danish National Prescription Register, we had complete nationwide information for all patients identifying all redeemed prescriptions for antipsychotic drugs from 6 to 42 months after inclusion into the study. Based on medication information from the Danish National Prescription Register, we divided participants in the following four groups: 1) Non-users, 2) compliant on medication, 3) stopped but resumed later with medication, and 4) stopped with medication. Results Of the 316 participants included in this study 94.3% had I diagnosis of schizophrenia. In the 3 years preceding the 5 years follow-up 28.2% did not redeem any prescriptions for antipsychotics drugs while 21.2% discontinued their treatment during the follow-up, 20.9% discontinued their treatment but resumed later and 29.7% remained in stable treatment. At the 5 years follow-up the 30.3% of the Never-users where in competitive employment, the mean psychotic symptom score were 1.4 SD (1.4) and negative symptoms 1.1 SD (0.9). Whiles these results were worse for patients Compliant on medication (17%, 1.9 SD (1.3), 1.8 SD (1.0)), Stopped but resumed medication (10.6%, 22.4 SD (1.4), 1.5 SD (1.0)) and Stopped medication (17%, 1.6 SD (1.3), 1.3 SD (1.0)), respectively. Of the Never-user 23.6% were in remission of both positive and negative symptoms, while this was only the case for 12.8% of those compliant on medication. Discussion This study is a naturalistic cohort study and we are unable to draw any conclusion regarding the causality between symptoms remission and use of antipsychotic medication. The study shows that a substantial proportion of patients, for several years, can discontinue their medical treatment without being re-hospitalized and with lower symptoms burden then patients who continue their medical treatment. Some patients discontinue their treatment but resume it later. These patients have approximately the same functional level and psychotypological scores as those who are compliant with their medical treatment and are treated with equivalent doses of antipsychotic at the time of the follow-up.

APA, Harvard, Vancouver, ISO, and other styles

47

Nakada, Masami. "The exponent of convergence of Poincaré series associated with some discontinuous groups." Tohoku Mathematical Journal 40, no. 3 (1988): 413–23. http://dx.doi.org/10.2748/tmj/1178227983.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Na, Tang Sufang and Wei. "Morrey Estimates for Nondivergence Parabolic Operators with Discontinuous Coefficients on Homogeneous Groups." Journal of Partial Differential Equations 23, no. 1 (June 2010): 1–15. http://dx.doi.org/10.4208/jpde.v23.n1.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Baklouti, Ali, and Imed Kedim. "Open Problems in Deformation Theory of Discontinuous Groups Acting on Homogeneous Spaces." International Journal of Open Problems in Computer Science and Mathematics 6, no. 1 (March 2013): 115–31. http://dx.doi.org/10.12816/0006162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kobayashi, Toshiyuki. "On discontinuous groups acting on homogeneous spaces with non-compact isotropy subgroups." Journal of Geometry and Physics 12, no. 2 (August 1993): 133–44. http://dx.doi.org/10.1016/0393-0440(93)90011-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Groupes discontinus'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles